Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)
about
Trypanosoma cruzi infection is a potent risk factor for non-alcoholic steatohepatitis enhancing local and systemic inflammation associated with strong oxidative stress and metabolic disordersOxidative Stress and Liver Cancer: Etiology and Therapeutic TargetsOxidative stress in obesity: a critical component in human diseasesmiRNA-103: molecular link between insulin resistance and nonalcoholic fatty liver disease.Non-alcoholic fatty liver disease in 2015.Coffee consumption and NAFLD: a community based study on 1223 subjects.Protective Effects of Celastrol on Diabetic Liver Injury via TLR4/MyD88/NF-κB Signaling Pathway in Type 2 Diabetic RatsBerberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress.CHIP(-/-)-Mouse Liver: Adiponectin-AMPK-FOXO-Activation Overrides CYP2E1-Elicited JNK1-Activation, Delaying Onset of NASH: Therapeutic Implications.Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.Glutamate dehydrogenase activator BCH stimulating reductive amination prevents high fat/high fructose diet-induced steatohepatitis and hyperglycemia in C57BL/6J mice.The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma.Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful?Caring for children with NAFLD and navigating their care into adulthood.Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease.Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors.Mechanisms of the prevention and inhibition of the progression and development of non-alcoholic steatohepatitis by genetic and pharmacological decoy receptor 3 supplementation.Changes in glucose transporter expression and nitric oxide production are associated with liver injury in diabetes.Oxidative stress balance is dysregulated and represents an additional target for treating cholangiocarcinoma.Effects of 4-nonylphenol on oxidant/antioxidant balance system inducing hepatic steatosis in male rat.Nonalcoholic fatty liver disease: Evolving paradigms.Salicornia Extract Ameliorates Salt-Induced Aggravation of Nonalcoholic Fatty Liver Disease in Obese Mice Fed a High-Fat Diet.ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.Toll-like receptor 4 is critical for the development of resection-associated hepatic steatosis.Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.Key Inflammatory Processes in Human NASH Are Reflected in Ldlr-/-.Leiden Mice: A Translational Gene Profiling Study.Development of experimental fibrotic liver diseases animal model by Carbon Tetracholoride.What Is the Optimal Dietary Composition for NAFLD?Establishment and Comparison of Juvenile Female Mouse Models of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
P2860
Q27304622-F7234570-0F48-4095-B03D-6D5DED9D3C46Q28071678-427E9C16-5EBA-452A-AFC8-43CE3C79877CQ28082703-014C764A-1307-4EDF-90B7-CB1909C06466Q34932524-BE46D50F-4CAB-481D-8DA0-ECC7780EE5FDQ35715883-BD9366DA-5AC8-4879-975A-0315466A3175Q35831047-7197C242-9E7A-4BF8-972C-428262D4D336Q36556309-9A32B72F-AA38-47FF-B2FF-06062E6D5BDEQ36560010-F971B482-C854-403F-A8A8-031E32B8AD3FQ37089148-12D71D7C-D1AB-495F-9819-CC5A1B64C8DBQ37146192-680E3733-BC73-49D2-ACB6-83B0BBD92B68Q37428035-BECD34DE-A68D-405E-AFF3-00FC65F19946Q37697255-D77EFAFF-4FC1-4EAC-80DC-C4E573991584Q38466831-948A2B94-38A3-407A-812B-6D989EA7D5A3Q38577570-5E4566F5-CE40-4978-8EC3-658EF787C01AQ38732142-341E3F77-9E42-4072-B8B1-37DE9840E6C4Q38972039-F0075725-3514-45E2-8DB1-291E887ECE48Q40380042-2419F2F8-CD8D-4BC5-B0D7-9BC7D251870AQ40564967-7B7A1B02-223D-43C7-908B-784BD5613A71Q40737823-7A1883B4-7EC1-4150-B16C-6CBE6BF4DCC3Q41679878-592D18E3-5550-494F-A39C-C9FC3DF4160FQ42695154-C5151812-9283-4606-9D91-6BCA879B11A9Q48007322-2192AF8A-8FA6-4216-9E4A-B4932AD8ADD9Q48275468-6D7E1DE7-28D1-4DBF-B3DF-A0AB31A3BF9CQ51082642-861879CF-C79F-4FB3-A403-F9F02D2C5D28Q53785179-25512877-9A37-4976-9019-CB2763FEE4CBQ55071759-0C14CE99-EF7E-4AB6-8B67-8F34C2F03D9DQ55251658-79F95A23-0CBC-4A7C-B6F2-E7EE762FDE23Q56701573-2A8FA305-5AC2-4EF7-ACE0-46F5EC5E1398Q58796980-8ADBA46C-C211-4D24-BA57-47BB3E7AA38A
P2860
Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Molecular mechanisms and new t ...... coholic steatohepatitis (NASH)
@ast
Molecular mechanisms and new t ...... coholic steatohepatitis (NASH)
@en
type
label
Molecular mechanisms and new t ...... coholic steatohepatitis (NASH)
@ast
Molecular mechanisms and new t ...... coholic steatohepatitis (NASH)
@en
prefLabel
Molecular mechanisms and new t ...... coholic steatohepatitis (NASH)
@ast
Molecular mechanisms and new t ...... coholic steatohepatitis (NASH)
@en
P2093
P2860
P921
P356
P1476
Molecular mechanisms and new t ...... coholic steatohepatitis (NASH)
@en
P2093
Akinobu Takaki
Daisuke Kawai
Kazuhide Yamamoto
P2860
P304
P356
10.3390/IJMS15057352
P407
P5008
P577
2014-04-29T00:00:00Z